Table 1: GFR targeted monoclonal antibodies (mAbs) for NSCLC therapy.

mAb nameTargeted GFRSourceCurrent developed phaseOngoing triala

CetuximabEGFRChimericIIINCT00408499
NCT00397384
NCT00946712
NCT00533949
NCT00368992
NCT01059188
NCT00867009
NCT00842712

CixutumumabIGF-1RHumanI/IINCT00955305
NCT01232452
NCT01263782
NCT00887159

EMD 72000 (Matuzumab) EGFRHumanized from mouseII

Figitumumab (CP-751,871)IGF-1RHumanIINCT00728390

Ganitumab (AMG 479)IGF-1RHumanINCT01327612

Necitumumab (IMC-11F8)EGRFHumanIIINCT00982111
NCT00981058
NCT01769391

Nimotuzumab EGFRHumanized from mouseIINCT01498562
NCT01393080

Olaratumab (IMC-3G3/LY3012207)PDGFR- HumanIINCT00918203

PanitumumabEGFRHumanINCT00979212
NCT01042288
NCT01038037

Ramucirumab (IMC-1121B)VEGF-2HumanIIINCT01160744
NCT01168973
NCT01703091

TrastuzumabHER-2Humanized from mouseIINCT00847366
NCT01148849

ahttp://www.clinicaltrial.gov/, access date March 16, 2013.